Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

AIMS/INTRODUCTION: Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator, fibroblast growth factor 21 (FGF21); a skeletal m...

Full description

Saved in:
Bibliographic Details
Published in:J Diabetes Investig
Main Authors: Yamakage, Hajime, Tanaka, Masashi, Inoue, Takayuki, Odori, Shinji, Kusakabe, Toru, Satoh‐Asahara, Noriko
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7232283/
https://ncbi.nlm.nih.gov/pubmed/31721467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13179
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items